Revance Therapeutics Inc
RVNC
$6.55
Closing
▼-0.15%
1D
▼-25.48%
YTD
RVNC
BBG001V0GBC7
Market cap
$682.38M
52 week high
$17.36
52 week low
$2.30
Volume
1,335,332
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$682.38M
Analysts' Rating
HOLD
Price Target (Mean)
9.32
Total Analysts
11
P/E
Operating Margin
-52.79%
Beta
0.99
Revenue Growth
20.17%
52 week high
$17.36
52 week low
$2.30
Div. Yield
%
EPS Growth
-37.93
Company Profile
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company’s portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane’s line of Resilient Hyaluronic Acid dermal fillers.
